Emeryville, California, April 2nd, 2024 – Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced the activation of
Emeryville, California, March 18th, 2024 – Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced the advancement of
Emeryville, California, June 6, 2023 – Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced that the California
March 14, 2023
Emeryville, California, October 18, 2022 – Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat cancer, today announced it has
Emeryville, California, October 17, 2022 – Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat solid tumors, today announced that the
Emeryville, California, September 28, 2022 – Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat cancer, today announced the publication
Figure 1: Overview of the TCRm-AFP/HLA-A*02 complex with the heavy and light chains of the TCRm Emeryville, California, August 3, 2022 — Eureka Therapeutics, Inc.,
Emeryville, California, June 6, 2022 — Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the
EMERYVILLE, Calif., and LOS ANGELES, May 31, 2022 — Eureka Therapeutics Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid
Alexa Willson has served as the Chief Financial Officer of Eureka Therapeutics since August 2022. Prior to joining the company, She was a Managing Partner of Cloudstone Venture Capital, an early-stage healthtech venture firm since October 2020. Cloudstone is also an investor of Eureka Therapeutics.
Ms. Willson has over 25 years of experience advising public and private companies on corporate finance, strategy, capital raising, valuation, mergers & acquisitions, and other matters. She has founded and run a midmarket investment banking boutique and worked with large Wall Street investment banks, including Kidder Peabody and Drexel Burnham.
Ms. Willson has served on private and non-profit boards and investment committees in various capacities. She teaches financial literacy. Ms. Willson holds a BA from Harvard and an MBA from Stanford Graduate School of Business.